Cyclacel pharmaceuticals reports third quarter 2022 financial results and provides business update

- oral fadraciclib daily dosing well tolerated in 18 evaluable patients treated in dose-escalation of phase 1/2 trial in advanced solid tumors and lymphoma -

CYCC Ratings Summary

CYCC Quant Ranking